Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis.
Ho KKY, Fleseriu M, Wass J, Katznelson L, Raverot G, Little AS, Castaño JP, Reincke M, Lopes MB, Kaiser UB, Chanson P, Gadelha M, Melmed S. Ho KKY, et al. Among authors: gadelha m. Lancet Diabetes Endocrinol. 2024 Mar;12(3):209-214. doi: 10.1016/S2213-8587(23)00382-0. Epub 2024 Jan 29. Lancet Diabetes Endocrinol. 2024. PMID: 38301678 Review.
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A; Pasireotide C2402 Study Group. Gadelha MR, et al. Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84. doi: 10.1016/S2213-8587(14)70169-X. Epub 2014 Sep 24. Lancet Diabetes Endocrinol. 2014. PMID: 25260838 Clinical Trial.
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R; Pasireotide B2305 Study Group. Schopohl J, et al. Pituitary. 2015 Oct;18(5):604-12. doi: 10.1007/s11102-014-0618-1. Pituitary. 2015. PMID: 25537481 Free PMC article. Clinical Trial.
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J; Pasireotide G2304 Study Group. Lacroix A, et al. Lancet Diabetes Endocrinol. 2018 Jan;6(1):17-26. doi: 10.1016/S2213-8587(17)30326-1. Epub 2017 Oct 12. Lancet Diabetes Endocrinol. 2018. PMID: 29032078 Clinical Trial.
Hypopituitarism.
Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S. Fleseriu M, et al. Among authors: gadelha m. Lancet. 2024 Jun 15;403(10444):2632-2648. doi: 10.1016/S0140-6736(24)00342-8. Epub 2024 May 9. Lancet. 2024. PMID: 38735295 Review.
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group. Pivonello R, et al. Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014 Mar 27. Clin Endocrinol (Oxf). 2014. PMID: 24533697 Clinical Trial.
A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group. Colao A, et al. N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743. N Engl J Med. 2012. PMID: 22397653 Free article. Clinical Trial.
Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).
Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Haberbosch L, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Reincke M, van der Lely AJ, Wass JAH, Melmed S, Casanueva FF. Giustina A, et al. Among authors: gadelha m. Pituitary. 2024 Jun 4. doi: 10.1007/s11102-024-01397-w. Online ahead of print. Pituitary. 2024. PMID: 38833044
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.
Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA, Boguszewski CL, Buchfelder M, Shimon I, Raverot G, Tóth M, Mezősi E, Doknic M, Fan X, Clemmons D, Trainer PJ, Struthers RS, Krasner A, Biller BMK. Gadelha MR, et al. J Clin Endocrinol Metab. 2024 Jun 3:dgae385. doi: 10.1210/clinem/dgae385. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 38828555
269 results